REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD

PROJECT SUMMARY/ABSTRACT Cognitive impairment, including Alzheimer’s Disease and Related Dementias (ADRD), and cardiopulmonary dysfunction following COVID-19, are components of the chronic syndrome known as Long COVID (LC). LC is an unprecedented public health crisis leading to cognitive, mental health, and functional disabilities for millions

of people living in the United States and around the world. Large epidemiologic studies have demonstrated that the risk of ADRD increases multifold in many old and young patients following even mild SARS-CoV-2 infection. Patients with LC also frequently experience profound limitations in physical function and exercise

intolerance that, when paired with ADRD, are life altering and result in inability to work and lead a family. Rapidly growing evidence links the clinical manifestations of LC to pathophysiologic mechanisms of abnormal inflammation and immune dysregulation. There is a driving, unmet need for robust clinical trials directly

targeting immune dysregulation to reduce ADRD and cardiopulmonary injury related to LC. Our central hypothesis is that immunomodulators may be the most effective treatment for these sequelae of LC. Baricitinib is an immunomodulator (JAK1/2 inhibitor) that is FDA-approved to treat acute COVID-19 infection as well as

certain autoimmune chronic diseases like rheumatoid arthritis. JAK1/2 signaling is a cardinal driver of both systemic and neuroinflammation. Our study, the Randomized trial EValuating Baricitinib on pERSistent nEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC), will enroll 500 patients with LC

and cognitive impairment at high risk for long-term ADRD across 4 sites to test the hypothesis that 6 months of baricitinib versus matched placebo will improve neurocognitive and physical function in LC. Aim 1 will measure the trajectory of neurocognitive function at enrollment, 6- and 12-months in baricitinib versus placebo patients

using an objective neuropsychological battery as well as patient-reported cognitive function. Aim 2 will measure physical function using cardiopulmonary exercise testing and other functional measures in addition to patient-reported physical symptoms in patients treated with baricitinib versus placebo. Aim 3 will evaluate the

effect of baricitinib versus placebo on plasma, cerebrospinal fluid, and neuroimaging inflammatory markers at enrollment, as well as 6- and 12-month follow-up study visits in patients with LC to identify inflammatory mediators of neuropsychological (ADRD) outcomes. The REVERSE-LC trial is novel in targeting immune

dysregulation and inflammation for patients with LC and is based on our growing understanding of the mechanism of this emerging, post-infectious cause of rapidly-acquired ADRD risk. Regardless of the outcome of REVERSE-LC, this study will provide crucial insights into treatment of ADRD, sequelae of COVID, and

disease pathogenesis. This investigation will also establish an innovative trial platform by which to test future interventions for rapidly-acquired neurocognitive dysfunction, cardiopulmonary disease, LC, and other age- related comorbidities leading to ADRD. It will advance the science of aging brain disease and disability.